Monthly Archives: June 2012

Neuralstem Updates ALS Stem Cell Trial Progress; Emory University Institutional Review Board Approves Amendment

Posted on by

ROCKVILLE, Md., June 5, 2012 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced that the Emory University Institutional Review Board (IRB) approved the amendment to the ongoing Phase I trial evaluating Neuralstem's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The amendment permits the return of three previously-treated patients to the trial to receive additional injections of cells. This modification to the protocol was approved earlier by the Food and Drug Administration (FDA). Implementation was contingent upon IRB approval, which has now been secured.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"Bringing patients back for a second set of injections should they meet the inclusion requirements at the time of surgery, or giving new patients both lumbar and cervical injections, is a major step forward toward testing the maximum safe dosing of our cell therapy," said Richard Garr, Neuralstem President & CEO. "We have been encouraged by the results of the trial to date, and are eager to commence treating patients with this increased dosage."

About the Study

The ongoing Phase I study is designed to assess the safety of Neuralstem's spinal cord stem cells (HSSC's) and transplantation technique in up to 18 patients with ALS.

The first twelve patients were all transplanted in the lumbar (lower back) region of the spine. Of these, the initial six (Cohort A) were all non-ambulatory with permanent paralysis. The first patient was treated on January 20, 2010. Successive surgeries have followed at the rate of one every one-to-two months. The first three patients (Cohort A1) were each treated with five unilateral HSSC injections in L2-L4 lumbar segments, while the next three patients (Cohort A2) received ten bilateral injections (five on each side) in the same region. The next six patients (Cohort B and C) were all ambulatory. Of these, the first three (Cohort B) received five unilateral injections in the L2-L4 region. The last three patients (Cohort C) in this study group received ten bilateral injections in the same region.

The trial was then approved to progress to cervical transplantations, with two cohorts of three patients (Cohort D and Cohort E). Cohort D has received five injections in the cervical region of the spinal cord. Cohort E will receive a total of fifteen injections, five in the cervical region and ten in the lumbar region.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

View post:

Neuralstem Updates ALS Stem Cell Trial Progress; Emory University Institutional Review Board Approves Amendment

Graham Elliot Opens Rock & Roll Church Restaurant

Posted on by

Graham Elliot combines food, music and spirituality at his new West Loop restaurant.

Chef Graham Elliot unleashed his latest food concept on Chicago's West Loop Tuesday with the official opening of g.e.b.

The new restaurant, located at 841 West Randolph Street, is being dubbed as a synergy between food, music and spirituality.

The decor is described as "church meets rock & roll," not surprising from the man who's curated Chowtown at Lollapalooza over the past couple of years.

A vintage Marshall amplifier stands in as the restaurants host stand and reclaimed church pews are used for seating in the 60-seat dining room. Record covers from '70s and '80s rock, pop and punk bands grace the menus and diners can request the albums be played during their meal. Catholic Saint Candles are also part of the decor, but replaced with the faces of notable Chicagoans like Mayor Emanuel and Michael Jordan.

Jacob Saben, who's been a member of Elliot's culinary team for four years, steps in as executive chef and offers seasonally rustic dishes under $20 that are made up of only three ingredients per plate, and broken down into five categories -- Cold, Hot, Pasta, Sea, Land and Sweet. (View Dinner Menu)

The restaurant offers lunch, dinner and weekend brunch service, and a late-night menu.

Oh, and no reservations are accepted. Because when you're rock & rollin' all night and partying every day, who has time to plan?

Continued here:

Graham Elliot Opens Rock & Roll Church Restaurant

SGT Awarded NASA Goddard Space Flight Center MSES Bridge Contract

Posted on by

GREENBELT, Md., June 5, 2012 /PRNewswire/ --SGT, Inc., a leading provider of Engineering, Science, Project Management, and Information Technology services, today announced that NASA has awarded a bridge contract to provide mechanical, thermal, and related engineering services to the Applied Engineering and Technology Directorate (AETD), in support of space technology development, Earth and Space science missions, and NASA's Exploration Program.

The MSES Bridge Contract is a follow-on contract to the current MSES IIA Contract that SGT was awarded in 2007. The MSES Bridge contract is a cost-plus-fixed-fee, indefinite-delivery/indefinite-quantity contract with a maximum ordering value of $285 million. The contract has a two-year effective ordering period beginning June 1, 2012.

The contract enables SGT to continue to provide state-of-the-art engineering and related services for the formulation, design, development, fabrication, integration, testing, verification, and operations of space flight and ground system hardware and software, including development and validation of new technologies to enable future space and science missions. The multidisciplinary services include mechanical and thermal engineering, structural and dynamic analysis, mechanical design, electro-mechanical system development, contamination and coatings, manufacturing, materials engineering, and integration & test.

SGT, Inc. is privately held and headquartered in Greenbelt, MD, USA. SGT, Inc. provides aerospace engineering, earth and planetary science modeling and analysis, information systems, project management, operational support and technical services to NASA, DOT, NOAA, USGS, DOD, and various other government and commercial organizations.

Read more from the original source:

SGT Awarded NASA Goddard Space Flight Center MSES Bridge Contract

Kagawa heads to Man United

Posted on by

5 June 2012 10:56

Manchester United have signed Borussia Dortmund attacker Shinji Kagawa for an undisclosed fee.

Manchester United have signed Borussia Dortmund attacker Shinji Kagawa for an undisclosed fee.

A statement on the Red Devils website read: "Manchester United is delighted to announce that it has agreed terms with both Borussia Dortmund and Shinji Kagawa for his transfer to the Club.

"The deal is subject only to the player medical and obtaining a UK work permit.

"These conditions are anticipated to be completed by the end of June. Further details will be announced in due course."

The 23-year-old had been linked with a move to Sir Alex Fergusons side more strongly since Chelsea secured the signature of Eden Hazard.

The transfer went through on June 5, just three days before Kagawa takes his place in Japan's side for their AFC Group B World Cup qualifier against Jordan.

The Japanese international helped win the Bundesliga for the second consecutive year with Borussia Dortmund last season and was named in the Bundesliga team of the season.

Read more:

Kagawa heads to Man United

Laotian star heads PH indie film cast

Posted on by

By: Bayani San Diego Jr. Philippine Daily Inquirer

DIRECTOR Adolfo Alix Jr. (left) worked nonstop in Palawan, recalls Ananda Everingham. PHOTO COURTESY OF PHOENIX FEATURES

Although he is best known for the Thai horror hit Shutter, which was remade as a Hollywood flick, Laotian-Australian actor Ananda Everingham has balanced his commercial work with involvement in art-house projects.

Visitors to Bangkok invariably encounter Everingham, whose face is on billboards and posters all over the city.

Time was when Thai cinema, powered by young indie visionaries, was among the most dynamic in the world, he recalled in an exclusive interview with the Inquirer.

Then it stagnated, he said. Government instability didnt help. Now, we are struggling.

To help revitalize the industry, he makes use of his celebrity by championing significant projects. I am in a unique position. I was never under contract with a studio, so its been easier for me to pursue and create my own projects, he noted.

He formed his own company, Halo, which has gone into film and TV production. As a producer, I started out a bit too idealistic, he admitted. Ive since realized that, to continue making the movies I want, I should make the company sustainable. My commercial work supports my more abstract, indie films.

In Thailand, he has three projects in the can: Fatherland, a political-action-drama about religious strife; Concrete Clouds, an art film set amidst the 1997 Asian economic crisis; and Shambala, a road movie about two brothers in Tibet.

He coproduced Shambala which, he explained, is Tibetan for nirvana.

Read more here:

Laotian star heads PH indie film cast

Federal satellite spy agency gives NASA two telescopes

Posted on by

WASHINGTON NASA has received a gift from an unexpected source the nation's satellite spy agency.

The space agency confirmed Monday that it received a pair of giant identical telescopes from the National Reconnaissance Office, which oversees the country's constellation of spy satellites. NASA says the spy agency built them and then decided it didn't need them. The transfer last summer was only recently declassified.

Even with this windfall, NASA has no money to launch the telescopes anytime soon.

The telescopes have mirrors similar in size to the famed Hubble Space Telescope, but they lack cameras and instruments essential for astronomy research. The telescopes are currently in upstate New York.

Scientists hope NASA will repurpose one of the telescopes to study mysterious dark energy.

The Associated Press

Read this article:

Federal satellite spy agency gives NASA two telescopes

Industrial Nanotech, Inc. Reports Significant Progress with India Sales Office

Posted on by

NAPLES, Fla.--(BUSINESS WIRE)--

Industrial Nanotech, Inc. (Pink Sheets:INTK), an emerging global leader in nanotechnology based energy saving and sustainable solutions announced today that the Companys plan to open a Corporate sales office in India is making significant positive progress. The company has already begun filling sales orders from new India manufacturing customers and has forged an alliance with an established equipment manufacturer in Bangalore who will act as a sales representative and applicator. The Company is also reviewing locations for warehousing and office space in Bangalore.

Since we began our plans to open a sales office in India, weve made significant progress, stated Francesca Crolley, VP of Business Development for Industrial Nanotech, Inc. Our marketing efforts have already produced over $18,000.00 US in sales to industrial manufacturers in India even before our office has officially opened. The companies there are truly progressive when it comes to energy savings, and have made it clear they are looking for the solutions that our patented Nansulate energy saving coatings provide. Additionally, after a meeting with a Bangalore based equipment manufacturer, we have forged a relationship where their company will not only promote the coating to their current clients, but also act as a sales representative and applicator for Nansulate in Southern India. This gives us a distinct advantage to grow sales and lead generation prior to our office opening, and should further accelerate our market penetration in this important country.

India's manufacturing sector kept up its steady expansion in May, with fast-rising output evened out by slowing growth of domestic order books. The HSBC manufacturing Purchasing Managers' Index (PMI), compiled by Markit, slipped marginally to 54.8 in May from 54.9 in April. It has stayed above the 50 mark, that separates growth from contraction, for a little over three years now. The PMI survey showed new export orders continued to grow at a strong pace in May, despite economic and political strife taking hold in Europe, one of India's main trading partners.

About Nansulate

Nansulate is the Company's patented product line of award winning, specialty coatings containing a nanotechnology based material and which are well-documented to provide the combined performance qualities of thermal insulation, corrosion prevention, resistance to mold growth, fire resistance, chemical resistance and lead encapsulation in an environmentally safe, water-based, coating formulation. The Nansulate Product Line includes industrial, residential, agricultural and solar thermal insulation coatings. Additional information about the Company and its products can be found at their websites, (www.inanotk.com) and (www.nansulate.com). Blog: http://www.nansulate.com/nanoblog, Twitter: http://www.twitter.com/NanoPioneer, Facebook: http://www.facebook.com/Nansulate.

About Industrial Nanotech Inc.

Industrial Nanotech Inc. is a global nanoscience solutions and research leader and member of the U.S. Green Building Council. The Company develops and commercializes new and innovative applications for sustainable nanotechnology which are sold worldwide.

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

Read more:

Industrial Nanotech, Inc. Reports Significant Progress with India Sales Office

Prospective Study Shows Favorable Overall Survival in Cancer of Unknown Primary Patients With Therapy Directed by …

Posted on by

CHICAGO--(BUSINESS WIRE)--

bioTheranostics, developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced study results showing that tumor profiling with its CancerTYPE ID molecular test helped guide site-specific chemotherapy and improve overall survival for patients with carcinoma of unknown primary site (CUP). The results were presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

The prospective trial, led by John Hainsworth, M.D., and F. Anthony Greco, M.D., of the Sarah Cannon Research Institute, utilized the CancerTYPE ID molecular classifier on 252 previously untreated CUP patients. Of the 194 patients who received assay-directed first-line therapy, results showed that the median overall survival was 12.5 months versus 4.7 months for patients receiving empiric therapy (p=0.02).

This was the first prospective study in which molecular profiling was used to direct site-specific therapy in CUP patients, producing a median overall survival that compares favorably with previous trials of empiric CUP therapy, said bioTheranostics Chief Scientific Officer Mark Erlander, Ph.D. Importantly, evidence from this study supports the use of molecular tumor profiling in the standard management of patients with CUP.

Richard Ding, CEO of bioTheranostics, said this study demonstrates the diagnostic and therapeutic utility of CancerTYPE ID in CUP management. These results show the value of CancerTYPE ID in improving treatment efficacy by directing site-specific therapy, he said. The results strengthen the rationale for molecular profiling in CUP management and show the value of precision medicine.

Ding said the results of this study are supported by two other studies presented at ASCO. This includes the first study to compare molecular classification versus the standard-of-care immunohistochemistry (IHC), which showed that CancerTYPE ID has a higher level of diagnostic accuracy than IHC (Abstract #e21019) in a series of 122 difficult-to-diagnose cases. A second blinded, multi-institutional study with three centers of excellence (UCLA, Mayo Clinic, and Massachusetts General Hospital)the largest validation study of a molecular classifier to date (Abstract #10588)showed that CancerTYPE ID has a high level of accuracy in predicting main tumor type and subtype, as well as stable performance in primary versus metastatic tumors, and in samples where specimen quantity was limited, as is common with core and fine needle biopsies.

Taken together, these results support the use of the CancerTYPE ID assay as a standardized diagnostic aid when primary tumor site is uncertain, Ding said. They also serve to solidify bioTheranostics position as a partner and solution provider in metastatic cancer.

CancerTYPE ID is being exhibited at bioTheranostics booth, No. 16097. To view the abstract, click here.

About bioTheranostics

bioTheranostics is the leading solution provider for metastatic cancer management, leveraging its unique expertise in expression profiling to develop a growing array of molecular diagnostic tests for cancer patients. The company operates a CLIA-certified, CAP-accredited diagnostic laboratory to perform its proprietary tests: the CancerTYPE ID molecular classification test; PRCISSM Precision Medicine, which includes biomarker profiles for non-small cell lung and colorectal cancers; and Breast Cancer IndexSM, which quantifies risk of recurrence of estrogen receptor positive, lymph node negative breast cancer. bioTheranostics, a bioMrieux company, is based in San Diego. For more information, visit http://www.biotheranostics.com.

Read the rest here:

Prospective Study Shows Favorable Overall Survival in Cancer of Unknown Primary Patients With Therapy Directed by ...

Roche Diagnostics enters strategic alliance with med fusion that recognizes company as a Roche Molecular Center of …

Posted on by

INDIANAPOLIS, June 5, 2012 /PRNewswire/ --Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the establishment of a strategic alliance with med fusion LLC in Lewisville, Texas, that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.

As a nationally recognized Roche MCOE, med fusion's molecular diagnostics laboratory will offer physicians and patients some of the latest and most advanced molecular technologies, such as Roche's cobas 4800 BRAF V600 Mutation Test, a companion diagnostic approved by the FDA in 2011 to identify patients who are eligible for treatment with the drug ZELBORAF (vemurafenib) for inoperable or metastatic melanoma, a deadly form of skin cancer.

Established in 2002, Roche's MCOE program is designed to create an alliance network that enables non-competing regional laboratories across the U.S. to collaborate and capitalize on scientific knowledge in molecular testing and, in turn, help accelerate the advancement of new test methods and technology.

"Roche is very pleased to welcome med fusion into the Molecular Center of Excellence alliance," said Whitney Green, senior vice president, molecular diagnostics at Roche Diagnostics Corporation. "We value their expertise and look forward to working together in implementing molecular technologies in the advancement of personalized medicine."

med fusion is one of 35 labs in the U.S. and three in Texas that have received this recognition and joined in this strategic partnership with Roche. "This relationship with Roche will help keep med fusion on the leading edge of technology and help ensure that we are supporting physicians and patients with the most advanced molecular technologies," said Dr. Thomas Lohmann, chief medical officer at med fusion. Keith Laughman, chief executive officer, added that the alliance "further supports med fusion's current and future collaborations as it continues to execute its targeted diagnostics initiatives."

About med fusion Headquartered in Lewisville, Texas, med fusion is an integrated, advanced laboratory and clinical trials service organization providing support to healthcare providers, biotech and pharmaceutical companies, through a patient-centric support model. Based in a 130,000- square foot facility, the company's clinical laboratory includes a dedicated test development and validation team to quickly meet the needs of clients. med fusion currently has over 300 well-trained employees, and a dedicated lab staff with an average of 16 years of experience.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: http://www.roche.com or http://www.roche-diagnostics.us.

COBAS is a trademark of Roche. All trademarks mentioned in this release are protected by law.

For further information, please contact:

RocheJennifer Zinn Vice President, Communications Roche Diagnostics Corporation Indianapolis, Indiana USA (317) 521-4245 jennifer.zinn@roche.com

See the article here:

Roche Diagnostics enters strategic alliance with med fusion that recognizes company as a Roche Molecular Center of ...

Alex Mind – Demand It (Original Mix) [Braslive Records] – Video

Posted on by

04-06-2012 19:26 Subscribe, Like, Comment, Share 😀 Subscribe button: PLEASE Like both Facebook Pages: ? PLEASE Follow Both Soundcloud Accounts: ? ? Add me as a friend on facebook 🙂 FOLLOW MY TWITTER! ------------------------------------------------------------------------------------- Buy Here: Follow Alex Mind!! Soundcloud: Facebook: ------------------------------------------------------------------------------------- Follow ElectrostepNetwork Records Facebook: Soundcloud: Youtube: Twitter: ------------------------------------------------------------------------------------- Send demos to for a possible release or get your track featured on ElectrostepNetwork! Please Title the message as Demo or Feature or your email will go in the spam folder! We'll get back to you if we like what we hear! ------------------------------------------------------------------------------------- To owners or copyright holders: If you dont want see your track in my channel, contact me and I will IMMEDIATELY remove the video. Thanks! Random Tags: deadmau5 skrillex dj way electronic house trancish 2009 2010 2010 top best dj blend david guetta electro dj producer feed me sofi bang software dubstep unique Professor Green freestylers ukf dubstep epic network lazy richrecords ...

Visit link:

Alex Mind - Demand It (Original Mix) [Braslive Records] - Video

Jean Goode – The Mind Traffic Sessions – Part 2 – Video

Posted on by

04-06-2012 21:52 Hey you, Thanks for checking out Part Two of my video! This was originally a 20 minute video that was rejected upon upload for being too long. If YouTube allows me to post longer videos in the future, I shall replace the two parts with the full version. Click here to view Part One: While editing this video and reviewing the many small clips I've collected to piece it together, I noticed how silly most of the clips were. I intended to make it a more serious video, but I can't seem to stop talking like a cartoon, and Teddy doesn't know how to be unfunny. So, this was the result. I hope you giggled as much as I did! For more information on the Mind Traffic project and to download the demos (free of course), visit Jean Goode Twitter Carlos Cortes Twitter: Asteroid Belt Twitter:

Read the original post:

Jean Goode - The Mind Traffic Sessions - Part 2 - Video

Boxee Launches Cloudee, Its Private Online Video-Sharing Service

Posted on by

Boxee is best known for software that makes online video more accessible on users TV screens. Now its working on something totally different helping users to take their own personal videos and making them available in the cloud. With the launch of Cloudee, the New York City-based startup is introducing a new service for users to store, access, and share their private videos with friends and family, all with an easy-to-use mobile app.

Of course, theres no shortage of mobile video-sharing applications or cloud storage applications. On the one hand, there are apps like Viddy and Socialcam, which aim to let users shoot or upload videos that theyve already shot, apply filters and share them on social networks like Twitter and Facebook. And there are services like Dropbox, which have opened up cloud storage and allow users to create folders and share them with others.

Cloudee sits somewhere in the middle: Its designed with sharing in mind, but private sharing. And while other cloud storage services enable you to share any type of file, Cloudee is all about video storage and sharing. The closest comparable might be private video-sharing service Givit.

The service is launching with a private, invite-only mobile application for the iPhone. Users can upload videos from the app, put them in folders and then choose which family or friends get to view them. They can then be accessed from the mobile app, from a web browser, or even from a users Boxee Box.

The introduction of a cloud offering and a supporting mobile application could be seen as a bit of a departure for Boxee, which has spent the last several years building software for PCs and connected devices like the eponymous Boxee Box. The cloud service is coming out, not long after the startup has backed away from building and supporting its PC software, showing that the future of the company might be in the cloud after all.

Also a bit of a departure is the focus on personal videos, as so much of its work in the past was focused on building software that made it easier to access the wealth of online and streaming video, first on PCs and later through the Boxee Box.

But Boxee clearly sees an opportunity for private video sharing in a market that isnt very well developed. The introduction of a cloud service for sharing of personal videos could also open the door for other cloud services from the startup. That includes enabling storage of other media files, for instance, or maybe even the ability to record videos and save videos in the cloud.

Boxee is a partially open-source freeware media player software platform that integrates personal locally stored media with Internet streaming media along with social networking features. Boxees social networking component allows users to share information about what they are watching or listening to with other boxee users or friends on social networks like Twitter, Facebook, etc. Since it is partially open source, users can create their own apps, plug-ins, and skins for it. The framework for Boxee is based on source...

Read this article:

Boxee Launches Cloudee, Its Private Online Video-Sharing Service

Biodesix’ Paul Beresford Joins 2012 BIO Panel for Personalized Medicine Commercialization

Posted on by

BOULDER, Colo.--(BUSINESS WIRE)--

Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that Paul Beresford, Ph.D., Vice President of Business Development and Strategic Marketing, will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine at the 2012 BIO International Conference being held in Boston, Mass. June 18-21, 2012.

The panel, Commercialization of Personalized Medicine: Stakeholders' Recipe For Success, will take place on Tuesday, June 19th from 3:45-5:00 p.m. EDT. Beresford joins Mara Aspinall, president and CEO of Ventana Medical Systems, a Roche Group; Glenn Miller, Vice President and Head of Personalized Medicine at AstraZeneca; and Ron Andrews, President, Medical Sciences at Life Technologies on the panel. With help from the panelists, who are successfully pioneering diagnostic products for personalized medicine, this session will gauge the power of collaboration to fuel personalized medicine and novel diagnostics, detail early successes, identify major challenges and debate the most attractive models for commercialization.

As personalized therapies continue to see rapid growth from the research side, this is the ideal time to create new business models that optimize the delivery of personalized medicine to patients by providing appropriate incentives to the businesses developing and commercializing these products, said Beresford. I am honored to join this group of innovators in discussing how to best approach this challenge.

Biodesix developed, validated and commercialized VeriStrat, a serum proteomic test currently available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer. The test identifies patients who are likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors (EGFRIs) using a simple blood draw. VeriStrat is based on ProTS, proprietary technology which harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles that characterize a patients condition or likely outcome in response to therapy. Biodesix collaborates with clinical investigators and also partners with biotechnology and pharmaceutical companies to develop diagnostics that can determine which patients are most likely to benefit from novel therapies.

About Biodesix: Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care. The Companys goal is to give physicians more information about the patient and their disease; understanding the clinically meaningful information contained within each patients molecular profile leads to better care and better outcomes. The Companys unique approach is based on ProTS, proprietary technology which harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles. Biodesix collaborates with clinical investigators to address critical clinical questions, and partners with biotechnology and pharmaceutical companies to develop diagnostics to select patients most likely to benefit from novel therapies. For more information about Biodesix, please visit http://www.Biodesix.com.

See the rest here:

Biodesix’ Paul Beresford Joins 2012 BIO Panel for Personalized Medicine Commercialization

American Liberty Petroleum Corp. Provides Progress Update for Nevada-Based Cortez Operation

Posted on by

BAKERSFIELD, Calif.--(BUSINESS WIRE)--

American Liberty Petroleum Corp. (OTCBB: OREO) (herein after "American Liberty" and/or "the Company") is pleased to provide a summary of the Company's recent progress on the Cortez Operation. The operation is located on the 3,840-acre Cortez lease in Gabbs Valley, Nye County, Nevada, and includes two wells: Cobble Cuesta 1-12 and Paradise 2-12.

In early May 2012, work resumed on the Paradise 2-12 well, including a fluid level test that indicated a 1920' fluid column in the well bore above the pump. Following the application of hot water and a new proprietary chemical formula treatment, the well produced additional fluid consisting of an oil/water mix. In total, approximately 29 barrels of crude was shipped to Foreland's Eagle Springs Refinery in neighboring White Pine County, representing the Company's second sale to Foreland. The BLM was also notified of the sale in order that the Company might secure "held by production" status on the Cortez lease.

The Company has continued to work with oil and gas consulting services firm Netherland, Sewell & Associates Inc. ("NSAI") to gather information toward determining next steps in the development of the Cortez operation. In particular, the Company is currently considering options that include:

1) Deepening the Cobble Cuesta 1-12 well

2) Deepening the Paradise 2-12 well

3) Drilling a new well based on information gained to date

4) Performing more seismic surveying prior to further exploration activities

NSAI is assisting the Company's assessment of all possible options by reviewing and evaluating the geological information currently available, and is providing American Liberty with their recommendations of the technical alternatives associated with each of the options, taking care to point out both the merits and potential challenges of each.

As of May 29, 2012, the Company had received an Authority For Expenditure (AFE) to re-enter the Cobble Cuesta 1-12 well, and an AFE to drill a new well in the Cortez lease. The AFEs act as budgetary documents that list the estimated expenses associated with the development activity in question: in the case of the well re-entry, an oil/gas well/re-enter with intermediate casing at 6000' and production casing at 8500', including perforate casing and frac; in the case of the new well, an oil/gas well with surface casing at 850', intermediate casing at 6000', and production casing at 8500', including perforate casing and frac.

See original here:

American Liberty Petroleum Corp. Provides Progress Update for Nevada-Based Cortez Operation

London eyes Argentine dispute over oil

Posted on by

LONDON, June 5 (UPI) -- The British government said it was studying statements from the Argentine government that plans to drill for oil off the Falkland Islands are illegal.

The Argentine government described exploration activity by British oil and natural gas explorers as "illegal and clandestine," reports British newspaper The Daily Telegraph.

Argentina is at odds with the British government over claims to the Falkland Islands. Buenos Aires maintains the islands are left over from the British colonial area and should fall under Argentine rule.

Argentina invaded Falkland Islands in 1982.

Argentine President Cristina Fernandez de Kirchner said British oil companies were operating "in a sovereign area" and not authorized to do so under national law.

London said Buenos Aires was working to scupper the economic livelihood of the islands.

"Hydrocarbon exploration in the Falklands is a legitimate commercial venture," the newspaper quoted the British government as saying. "We are studying Argentina's remarks carefully and will work closely with any company potentially affected to ensure that the practical implications for them are as few as possible."

Read this article:

London eyes Argentine dispute over oil

Consolidated Water Co. Ltd. Declares Third Quarter Cash Dividend

Posted on by

GEORGE TOWN, GRAND CAYMAN, CAYMAN ISLANDS--(Marketwire -06/05/12)- Consolidated Water Co. Ltd. (CWCO) today announced that its Board of Directors has declared a quarterly cash dividend of $0.075 per share.

The dividend is payable July 31, 2012 to shareholders of record at the close of business July 1, 2012.

CWCO-D

About Consolidated Water Co. Ltd.

Consolidated Water Co. Ltd. develops and operates seawater desalination plants and water distribution systems in areas of the world where naturally occurring supplies of potable water are scarce or nonexistent. The Company operates water production and/or distribution facilities in the Cayman Islands, Belize, the British Virgin Islands and The Commonwealth of The Bahamas. Additional information on the Company is available on its website at http://www.cwco.com.

Visit link:

Consolidated Water Co. Ltd. Declares Third Quarter Cash Dividend

Platypus Populations on Small Australian Islands Show Lack of Genetic Diversity, High Risk of Disease

Posted on by

Last year we learned that climate change could soon make Australia too hot for the cold-loving, iconic platypus (Ornithorhynchus anatinus). Now we have word of a new threat to these unique, egg-laying mammals: inbreeding, which has put the platypuses living on two small Australian islands at enhanced risk of disease.

According to research published March 28 in Ecology and Evolution and May 4 in the Journal of Heredity, the platypus populations on mainland Australia and its island state Tasmania have perfectly normal levels of genetic diversity. But populations on two nearby islands arent in as good shape. University of Sydney doctoral student Mette Lillie, lead author of the Journal of Heredity paper, says platypuses on the 1,100-square-kilometer King Islandlocated off the coast of Tasmania and separated genetically from the mainland by the last ice age 14,000 years agonow show no diversity in their major histocompatibility complex (MHC) gene, putting them at high risk of an epidemic disease. If you have lots of variation in the MHC gene, it means the population is better able to resist disease and pathogens, she told the Australian Broadcasting Corp (ABC). Lillie was one of the researchers who sequenced the platypus genome in 2010.

The Ecology and Evolution paper, by researchers from the University of Melbourne and other organizations, said the King Island population shows one of the lowest levels of genetic diversity ever found in any vertebrate population.

Platypuses on the 4,400-square-kilometer Kangaroo Island, located off the state of South Australia, arent doing much better. But that population was introduced there by humans in the 1930s and 40s, and Lillie says the lack of genetic diversity is to be expected from such a small population with no influx of new breeding stock.

Lillie told ABC Radios PM news program that genetic diversity problems can often be solved by introducing animals from a different population, but that would be too risky on King Island because any newcomers to the island could bring a new disease for which the existing population would be unprepared.

The most serious disease afflicting platypuses today is ulcerative mucormycosis, a fungal disease affecting the species on Tasmania. The diseasemuch like the devil facial tumor disease that affects Tasmanian devilscauses nasty, ulcerated lesions on animals, which can prove fatal when the wounds become infected. Mucormycosis is caused by Mucor amphibiorum, a fungus native to mainland Australia, where it does not affect the resident platypuses. The disease was first observed on Tasmania in 1982. Experts suspect it arrived on Tasmania via illegally transported green tree frogs.

Platypusesone of five egg-laying mammal species now living in the worldwere overhunted by fur traders until the early 20th century but are now protected under Australian law. They are also the sole living species in their genus and one of worlds only venomous mammals.

Meanwhile, life on small islands may actually benefit another Australian species, the eastern quoll (Dasyurus viverrinus), which disappeared from mainland Australia decades ago. The marsupials can now only be found on Tasmaniawhere their populations have declined 50 percent in the past 10 yearsand Tasmanias nearby Bruny Island (362 square kilometers), where University of Tasmania researcher Bronwyn Fancourt has found that they are flourishing. Its too early to say why Bruny has provided a safe haven, but the decline on Tasmania has been linked to feral cats. Ironically, eastern quolls are also known as eastern native cats even though they are not felines. The genetic diversity of the eastern quoll has not yet been studied.

Photos: Platypus by Cha222 via Flickr. Eastern quoll by Matthias Siegel via Flickr. Used under Creative Commons license

View post:

Platypus Populations on Small Australian Islands Show Lack of Genetic Diversity, High Risk of Disease